TGF-beta (all active isoforms: TGF-b1, TGF-b2, TGF-b3)

Class

Monoclonal antibody (pan-TGFbeta neutralizing antibody)

Pathway

TGF-beta/SMAD signaling (immunosuppressive tumor microenvironment)

Transforming growth factor-beta (TGF-beta) is a family of three related signaling proteins (TGF-b1, TGF-b2, TGF-b3) that cells secrete to regulate growth, tissue repair, and immune activity. Under normal conditions, TGF-beta helps maintain tissue balance by limiting excessive cell proliferation and moderating immune responses so that inflammation resolves properly. In cancer, tumors frequently exploit this same pathway to their advantage: by producing high levels of TGF-beta, they suppress the surrounding immune cells, promote a fibrous tissue environment that shields the tumor, and encourage cells to become more invasive. A pan-TGF-beta neutralizing antibody is designed to bind and block all three isoforms simultaneously, preventing them from engaging their receptors on target cells. The therapeutic rationale is to reverse this immunosuppressive tumor microenvironment, restoring the ability of immune cells, particularly T cells, to recognize and attack cancer cells. Because TGF-beta signaling operates broadly across nearly all tissues, this mechanism is being explored mainly in oncology, often alongside other immune-modulating approaches, with the goal of converting tumors that are poorly responsive to immune-based treatment into ones that respond more effectively. The breadth of isoform coverage distinguishes this approach from strategies that target only one TGF-beta subtype.